Caribou Biosciences Inc

Caribou Biosciences conducts preclinical studies of its drug candidates on animals to assess safety and efficacy. The company’s research protocols, as described in its own reports, involve administering single doses of experimental therapies to animal cohorts and monitoring them over time. This reliance on animal testing is a standard but contested component of the biopharmaceutical development process.

Cruelty Free International, which maintains the exclusion list citing Caribou, argues that such animal-based drug tests lack scientific validity for human outcomes. A 2025 audit of U.S. laboratories documented widespread animal welfare violations, indicating systemic issues in research animal care. While no company-specific violations are cited for Caribou in the provided evidence, its business model is fundamentally dependent on animal experimentation. The company has not published a formal commitment to developing or adopting non-animal testing methods.